Pharmaceuticals
Xinhua Silk Road: 52nd Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi
BEIJING, Oct. 20, 2021 /PRNewswire/ -- The 52nd Zhangshu National Traditional
Chinese Materia MedicaTrade
2021-10-20 17:27
4163
Bill & Melinda Gates Foundation Commits up to $120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources
Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines SEATTLE, Oct. 20, 2021 /PRNewswire/ -- The Bill & Melinda Gates Foundation announced today a comm...
2021-10-20 13:29
3114
CStone received China NMPA IND acceptance for lorlatinib in Chinese patients with ROS1-positive advanced NSCLC
SUZHOU, China, Oct. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, today announced that the investigational new drug (...
2021-10-20 08:00
4516
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...
2021-10-20 05:08
2571
Excelra Announces Addition of Sudip Nandy to its Board of Directors
HYDERABAD, India, Oct. 19, 2021 /PRNewswire/ -- Excelra, a leading Data and Analytics provider for Life Science organizations, announced the appointment of Sudip Nandy to the company's board of directors effective 1st October 2021. Mr. Nandy is an acclaimed business leader with over 30 years of e...
2021-10-19 21:00
8207
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189, which is the company's...
2021-10-19 12:56
2417
CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections
LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2021-10-19 09:00
2257
Australian businesses invited to advance the future of healthcare technologies in the Medtronic APAC Innovation Challenge
SYDNEY, Oct. 19, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in healthcare technology, invites Australian businesses to participate in the newly launchedMedtronic APAC Innovation Challenge (MAIC). Providing an opportunity for innovators in the region to pitch and advance the...
2021-10-19 06:51
4305
The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics
SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a research team led by Prof. Shaomeng Wang, ...
2021-10-18 22:42
8613
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2021-10-18 20:00
2206
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-10-18 08:00
5436
AFT Launches NZ-Made, 100% Natural, 90% Recyclable Hemptuary® Skincare Range
SYDNEY, Oct. 18, 2021 /PRNewswire/ -- Skincare mavens and beauty gurus have a
new product to not only feel good in but feel good about – AFT Pharmaceuticals'
new skincare range, Hemptuary®, is made inNew Zealand from 100% natural
ingredients and has packaging that is 90% recyclable.
2021-10-18 05:00
2688
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
2021-10-15 12:44
2514
International Biopharma Industry Week Shanghai 2021 Opens
SHANGHAI, Oct. 15, 2021 /PRNewswire/ -- On October 11, the International Biopharma Industry Week Shanghai 2021, under the guidance of the Shanghai Biomedical Industry Development Leading Group, the inaugural International Biopharma Industry Week Shanghai (IBIWS) is co-hosted by Shanghai Biomedica...
2021-10-15 12:22
4658
Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx
SHANGHAI, Oct. 15, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Abbisko (SEHK:2256), a clinical-stage biopharmaceutical company, listed on the main board of the Hong Kong Stock Exchange onOctober 13. The issue price isHK$ 12.46 per share, representing a market cap of HK$ 8.753 ...
2021-10-15 12:00
4684
Interim Results Of A Pioneering Combination Study In Argentina With More Than 1,000 Participants Confirm The One-shot Sputnik Light Vaccine (The First Component Of The Sputnik V Vaccine) Is An Effective Universal Booster For Vaccines Produced By AstraZeneca, Sinopharm, Moderna And Cansino Inducing Strong Immune Response And Showing High Safety Profile. Combination Of AstraZeneca And Sputnik Light Vaccines Showed High Immunogenicity Results.
* One-shot Sputnik Light is the first component of the Sputnik V vaccine, the world's first registered vaccine against coronavirus. Sputnik V pioneered the heterogeneous boosting approach (a "vaccine cocktail" using human adenovirus serotype 26 as the first component and human adenovirus seroty...
2021-10-15 05:26
2635
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin ...
2021-10-14 20:46
4033
A China-developed COVID-19 vaccine is conducting clinical trial in Philippines
CHENGDU, China, Oct. 14, 2021 /PRNewswire/ -- Philippines is currently conducting, along with other countries includingIndonesia, Kenya, and Mexico, a Phase III clinical trial of Recombinant COVID-19 Vaccine (Sf9 cells) produced by WestVac Biopharma Co., LTD and National Key Laboratory of Bioth...
2021-10-14 12:58
2643
One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows
* The vaccine is more than 75% effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalizations. * Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decli...
2021-10-13 20:30
5765
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will...
2021-10-13 20:30
4361
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
19487
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
19413
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
17379
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
13037